November 13, 2018 06:59 AM EST

As Roivant’s unicorn valuation swells to $7B, Ramaswamy scoops up $200M to back a new burst of startups

John Carroll

Editor & Founder

Vivek Ramaswamy never hid his ambitions in swiftly building Roivant into a global biopharma player. But now he’s offering some new details about just how …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Roivant’s unicorn valuation swells to $7B, Ramaswamy scoops up $200M to back a new burst of startups

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

As Roivant’s uni­corn val­u­a­tion swells to $7B, Ra­maswamy scoops up $200M to back a new burst of star­tups

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

As Roivant’s unicorn valuation swells to $7B, Ramaswamy scoops up $200M to back a new burst of startups